T/R potency <5% [Regulatives / Guidelines]

posted by dshah  – India, 2022-09-09 12:48 (1028 d 00:12 ago) – Posting: # 23282
Views: 4,578

Hi Achievwin!
Unlike Health Canada, there is no provision for potency correction in FDA.
So if the difference is more, there is higher probability to find difference in PK parameters for treatments, which ultimately affects BE outcome.
It's best to have less difference in Assay of Test and Reference for any BE study.
Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
23,425 posts in 4,928 threads, 1,683 registered users;
38 visitors (0 registered, 38 guests [including 12 identified bots]).
Forum time: 13:01 CEST (Europe/Vienna)

You can do one of two things; just shut up,
which is something I don’t find easy,
or learn an awful lot very fast,
which is what I tried to do.    Jane Fonda

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5